针对新型冠状病毒（SARS-CoV-2）所致的肺炎（COVID-19）疫情，国家卫生健康委员会、国家中医药管理局在2020年1月22日发布的《新型冠状病毒感染的肺炎诊疗方案（试行第三版）》中首次提出了中医治疗的方案，并逐步更新至第七版。确诊的COVID-19重症患者多在发病一周后岀现呼吸困难和/或低氧血症，需要给予呼吸支持和循环支持，通过文献调研发现补气活血中药可有效改善肺炎相关疾病低氧血症，因此总结归纳了现有补气活血中药治疗肺炎相关疾病低氧血症的临床应用和作用机制研究进展，为COVID-19的临床用药提供参考。

For SARS-CoV-2-induced pneumonia, "Diagnosis and Treatment of Novel Coronavirus Pneumonia (trial version 3)" released by the National Health Commission of the People's Republic of China and the National Administration of Traditional Chinese Medicine on January 22, 2020, first proposed the traditional Chinese medicine (TCM) treatment plan, which was gradually updated to the seventh edition. Patients diagnosed with severe COVID-19 often developed dyspnea and/or hypoxemia one week after onset, requiring respiratory support and circulation support. Through literature research, it was found that Chinese materia medica (CMM) with tonifying qi and activating blood effect could effectively improve hypoxemia of pneumonia-related diseases. This article summarizes the mechanism and clinical application of tonifying qi and activating blood CMM in the treatment of novel coronavirus pneumonia-associated hypoxemia, and provides a reference for clinical treatment of COVID-19.

R285

国家"重大新药创制"科技重大专项（2017ZX09301005）